- Home
- News
- Articles+
- ABOUT THE LAW
- AWARDS & ACCOLADES
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Legal Era TV
- Events
- News
- Articles
- ABOUT THE LAW
- AWARDS & ACCOLADES
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Legal Era TV
- Events
China regulator penalizes two pharma firms for monopoly Antitrust crackdown has been taking place on industries since 2020The China regulator has fined two pharma firms, Grand Pharmaceutical and Wuhan Healcare Pharmaceuticals, for entering into a deal and monopolizing the trade. It fined Grand Pharmaceutical 136 million yuan ($19.68 million) and confiscated 149 million yuan of...
ToRead the Full Story, Subscribe to 
Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion
China regulator penalizes two pharma firms for monopoly
Antitrust crackdown has been taking place on industries since 2020
The China regulator has fined two pharma firms, Grand Pharmaceutical and Wuhan Healcare Pharmaceuticals, for entering into a deal and monopolizing the trade.
It fined Grand Pharmaceutical 136 million yuan ($19.68 million) and confiscated 149 million yuan of illegal revenue and penalized Wuhan Healcare 4.13 million yuan and confiscated over 30 million yuan of its revenue.
Since late 2020, Chinese regulators began antitrust crackdowns on multiple industries, particularly, technology companies such as Alibaba Group.